Is There Visceral Adipose Tissue (VAT) Intracellular Hypercortisolism in Human Obesity?

Abstract

The fact that obesity is a prominent feature of Cushing’s syndrome (systemic hypercortisolism of adrenocortical origin) stimulated a 40-year search for evidence of systemic hypercortisolism in human obesity. That search has failed to find such evidence. For the past 15 years, however, studies have been done to evaluate a possible alternative type of hypercortisolism in obesity, namely visceral adipose tissue (VAT) intracellular hypercortisolism. The current review summarizes the evidence published so far about this possibility. There have been three types of evidence studied: direct measurement of the VAT levels of 11β-hydroxysteroid dehydrogenase type I (11-HSD-1), which converts biologically inactive cortisone to biologically active cortisol; direct measurement of splanchnic cortisol production; and evaluation of the effect of a specific inhibitor of 11-HSD-1 on metabolic abnormalities associated with obesity, particularly diabetes mellitus. The results are complex and difficult to interpret. Our conclusion is that the presence of VAT intracellular hypercortisolism in human obesity is possible but unlikely.

Key words

obesity - intracellular cortisol production - 11β-hydroxysteroid dehydrogenase

• References

• 1 Salehi M, Ferenczi A, Zumoff B. Obesity and cortisol status. Horm Metabol Res 2005; 37: 193-197
• 2 Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing’s syndrome of the omentum”?. Lancet 1997; 349: 1210-1213
• 3 Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi M-C, Grino M. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type I in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002; 87: 2701-2705
• 4 Tomlinson JW, Sinha B, Bujalska M, Hewison M, Stewart PM. Expression of 11beta-hydroxysteroid dehydrogenase type I in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002; 87: 5630-5635
• 5 Mariniello B, Ronconi V, Rilli S, Bernante P, Boscarso M, Mantero F, Giacchetti G. Adipose tissue 11beta-hydroxysteroid dehydrogenase type I expression in obesity and Cushing’s syndrome. Eur J Endocrinol 2006; 155: 435-441
• 6 Desbriere R, Vuaroqueaux V, Avhard V, Boullu-Ciocca S, Labuhn M, Dutout A, Grino M. 11Beta-hydroxysteroid dehydrogenase type I mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity 2006; 14: 794-798
• 7 Walker BR, Andrew R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type I and metabolic disease. Ann NY Acad Sci 2006; 1083: 165-184
• 8 Aldhahi W, Mun E, Goldfine AB. Portal and peripheral cortisol levels in obese humans. Diabetologia 2004; 47: 833-836
• 9 Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson MC, Toffolo G, Cobelli C, Rizza RA. Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J Clin Endocrinol Metab 2005; 90: 3929-3926
• 10 Andrew R, Westerbacka J, Wahren J, Yki-Jarvinen H, Walker B. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 2005; 54: 1364-1370
• 11 Stimson RH, Andersson J, Andrew R, Redhead DN, Karpe F, Hayes PC, Olsson T, Walker BW. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type I in humans. Diabetes 2009; 58: 46-53
• 12 Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM. 11beta-hydroxysteroid dehydrogenase type I: a tissue-specific regulator of glucocorticoid response. Endocrine Rev 2004; 25: 831-866
• 13 Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huiber R. The 11beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type-2 diabetes inadequately controlled by metformin. Diabetes Care 2010; 33: 1516-1522